Loving the way this is playing out today doesn't get much better than this! The trial will focus on providing therapies to limited option patients. Data collected will be compared against a control segment of standard, non-treated patients. Additionally, outcomes and safety data from Arm 2 patients will be compared against Arm 1 to establish differentials in therapy modalities. $CIHN
(0)
(0)
BioStem Technologies, Inc. (BSEM) Stock Research Links